Physician

Rajinder S. Grover, M.D.

According to 2025 Medicare claims, Rajinder Grover, M.D. (NPI: 1376561225) practices hematology in the Phoenix-Mesa-Chandler, AZ market, with the plurality of this provider's patient population coming from Maricopa, AZ. This provider's primary affiliated billing organization is PALO VERDE HEMATOLOGY ONCOLOGY LTD. (NPI: 1447272372; TIN: 860416050) and primary practice location at 85251-4548. Grover is affiliated with the Banner Health Network (ACO ID: A3229), participating under the MSSP model.

Grover's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 432 traditional Medicare patients, billed 235,659 HCPCS/CPT codes, and received $4,313,281 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,876 prescription claims across 277 beneficiaries totaling $3,557,051 in drug costs, led by Ibrance (Palbociclib). 2020 DME data shows 95 claims. Open Payments data shows 42 records totaling $2,373. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $875,538 to $4,313,281. Similarly, Part D prescription costs have risen steadily, from $192,368 to $3,557,051. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	323	71,813	$875,538
2016	389	153,918	$1,826,699
2017	394	221,759	$3,124,229
2018	398	235,932	$3,229,457
2019	370	187,376	$2,679,389
2020	354	204,510	$2,868,267
2021	407	159,671	$2,382,813
2022	393	159,584	$2,472,898
2023	396	242,223	$3,068,346
2024	432	235,659	$4,313,281

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	88	499	$192,368
2016	139	1,000	$479,821
2017	176	1,485	$969,286
2018	184	1,562	$1,225,906
2019	198	1,565	$1,881,766
2020	225	1,513	$2,124,677
2021	262	1,534	$3,152,459
2022	222	1,095	$2,062,306
2023	243	1,245	$2,444,507
2024	277	1,876	$3,557,051

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	28	$14,961
2016	N/R	61	$20,355
2017	N/R	N/R	N/R
2018	N/R	90	$29,761
2019	N/R	227	$84,763
2020	N/R	95	$11,273
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	108	509	$133
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	242	610	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	118	152	$65
36415	Insertion of needle into vein for collection of blood sample	252	1,001	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	261	1,370	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	24	672	$362,375
Calquence	Acalabrutinib Maleate	31	930	$319,313
Imbruvica	Ibrutinib	14	392	$229,619
Procrit	Epoetin Alfa	138	2,730	$221,897
Lynparza	Olaparib	12	360	$199,742

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	42	$2,373	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rajinder S. Grover, M.D.?

Tedicare shows public-source Medicare data for Rajinder S. Grover, M.D. (NPI 1376561225), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rajinder S. Grover, M.D. have ACO affiliation data?

Rajinder S. Grover, M.D. is shown with ACO affiliation data for Banner Health Network (MSSP, ACO ID A3229).

What billing organization is linked to Rajinder S. Grover, M.D.?

Rajinder S. Grover, M.D. is linked to PALO VERDE HEMATOLOGY ONCOLOGY LTD. (billing NPI 1447272372) in the available physician profile data.

Does Rajinder S. Grover, M.D. have Open Payments data?

Rajinder S. Grover, M.D. has 42 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.